Michael Raab Sells 45,982 Shares of Ardelyx (NASDAQ:ARDX) Stock

Ardelyx, Inc. (NASDAQ:ARDX) CEO Michael Raab sold 45,982 shares of the firm’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $5.85, for a total transaction of $268,994.70. Following the sale, the chief executive officer directly owned 1,856,986 shares of the company’s stock, valued at approximately $10,863,368.10. This trade represents a 2.42% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Ardelyx Stock Performance

NASDAQ:ARDX opened at $6.56 on Wednesday. The company has a quick ratio of 4.11, a current ratio of 4.31 and a debt-to-equity ratio of 1.21. Ardelyx, Inc. has a twelve month low of $3.21 and a twelve month high of $8.40. The company has a fifty day moving average of $6.77 and a 200-day moving average of $6.14. The firm has a market capitalization of $1.61 billion, a P/E ratio of -26.24 and a beta of 0.57.

Ardelyx (NASDAQ:ARDX) last posted its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.03). Ardelyx had a negative return on equity of 40.63% and a negative net margin of 15.12%.The company had revenue of $125.22 million during the quarter, compared to analyst estimates of $118.04 million. During the same quarter in the previous year, the business posted $0.02 earnings per share. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that Ardelyx, Inc. will post -0.18 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ARDX. Piper Sandler raised Ardelyx from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $10.00 to $16.00 in a research note on Thursday, January 8th. Wedbush reaffirmed an “outperform” rating and set a $19.00 target price on shares of Ardelyx in a research report on Monday. Raymond James Financial reiterated a “strong-buy” rating and issued a $19.00 target price on shares of Ardelyx in a report on Thursday, January 8th. Jefferies Financial Group restated a “buy” rating and set a $15.00 price target on shares of Ardelyx in a research note on Tuesday, January 27th. Finally, Citigroup raised their price objective on shares of Ardelyx from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Friday, January 9th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $15.09.

Trending Headlines about Ardelyx

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Director David M. Mott bought 333,333 shares (~$1.95M) at about $5.84, increasing his stake ~11.2% — a strong insider vote of confidence that can support the stock. Read More.
• Positive Sentiment: Ardelyx announced a multi‑year partnership with the LPGA to raise awareness and reduce stigma around digestive health — a marketing push that could help commercial uptake of XPHOZAH/brand awareness over time. Read More.
• Positive Sentiment: Analyst support remains strong — Wedbush reaffirmed an outperform with a $19 target and other firms (BTIG, HC Wainwright, Jefferies, Citi) have reiterated buys or raised targets, which can attract buyers. Read More. Read More.
• Neutral Sentiment: Quarterly revenue beat estimates ($125.2M vs. $118.0M) and revenue grew ~7.8% y/y — constructive fundamental data but partially offset by the EPS miss.
• Neutral Sentiment: Post‑results commentary includes valuation and guidance analysis (coverage piece on Yahoo Finance reviewing 2025 results and 2026 guidance) — useful for longer‑term investors assessing upside vs. risk. Read More.
• Negative Sentiment: Ardelyx missed EPS expectations (reported a small loss vs. a modest expected profit), which triggered a post‑earnings pullback and adds short‑term risk for the shares. Read More.
• Negative Sentiment: Multiple insiders (including CEO Michael Raab, CFO Susan Hohenleitner and several executives) sold shares around Feb. 20 (CEO sold ~45,982 shares), which can be perceived as profit‑taking and may pressure sentiment despite the director buy. Read More.

Institutional Trading of Ardelyx

Hedge funds and other institutional investors have recently bought and sold shares of the company. DCF Advisers LLC bought a new position in Ardelyx in the 2nd quarter valued at $39,000. Brighton Jones LLC purchased a new stake in shares of Ardelyx in the second quarter worth $40,000. First Horizon Corp boosted its stake in Ardelyx by 120.4% during the fourth quarter. First Horizon Corp now owns 7,906 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 4,319 shares during the period. SBI Securities Co. Ltd. grew its position in Ardelyx by 147.0% during the third quarter. SBI Securities Co. Ltd. now owns 10,253 shares of the biopharmaceutical company’s stock worth $56,000 after buying an additional 6,102 shares in the last quarter. Finally, Swiss Life Asset Management Ltd purchased a new position in Ardelyx during the third quarter worth about $57,000. Institutional investors own 58.92% of the company’s stock.

Ardelyx Company Profile

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.